Description
SITADOL-M 50/1000 Tablet contains Sitagliptin 50 mg and Metformin 1000 mg, a combination of two oral antidiabetic medicines used to help manage blood glucose levels in adults with type 2 diabetes mellitus. Sitagliptin belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class, while metformin is a biguanide that primarily reduces glucose production by the liver and improves insulin sensitivity.
This combination may be prescribed alongside dietary management and physical activity when a healthcare professional determines that both active ingredients are appropriate. Treatment suitability depends on the patient’s blood glucose levels, kidney function, current medicines and overall clinical condition.
CardianCare is associated with cardiac and diabetic healthcare products. Businesses researching a Sitagliptin 50 mg + Metformin 1000 mg Tablets manufacturer India should verify the actual manufacturing source, product authorization, approved specifications and current availability before procurement.
For procurement teams evaluating a Sitagliptin 50 mg + Metformin 1000 mg Tablets manufacturer and supplier India, important checks include composition accuracy, approved labelling, packaging details, batch traceability, shelf life and documented commercial supply arrangements. CardianCare’s specific role in manufacturing or supplying this formulation requires direct confirmation.
2. Key Ingredient
Sitagliptin 50 mg + Metformin 1000 mg
Composition:
– Sitagliptin – 50 mg
– Metformin – 1000 mg
Sitagliptin 50 mg
Sitagliptin is an oral antidiabetic medicine classified as a DPP-4 inhibitor. It slows the breakdown of incretin hormones, which help regulate glucose-dependent insulin secretion and glucagon release when blood glucose levels are elevated.
Metformin 1000 mg
Metformin belongs to the biguanide class of antidiabetic medicines. It primarily reduces glucose production in the liver and improves the body’s response to insulin, helping support blood glucose regulation.
These ingredients act through complementary mechanisms. The appropriate combination and strength must be determined by the treating clinician based on the patient’s treatment requirements and the approved product information.
Businesses researching a Sitagliptin 50 mg + Metformin 1000 mg pharmaceutical company India should verify the brand owner, marketing authorization holder and actual manufacturer using reliable company and product documentation.
A Sitagliptin 50 mg + Metformin 1000 mg medicine manufacturer India enquiry should include confirmation of the licensed manufacturing facility, product approval, batch documentation and applicable quality standards. These details should not be inferred from the brand name alone.
3. Key Benefits
Potential clinical benefits when prescribed appropriately include:
1. Blood glucose management: Helps improve glycaemic control in adults with type 2 diabetes.
2. Complementary mechanisms: Combines a DPP-4 inhibitor with a biguanide to act through different pathways involved in glucose regulation.
3. Glucose-dependent activity: Sitagliptin supports insulin secretion primarily when blood glucose is elevated.
4. Reduced hepatic glucose production: Metformin primarily reduces the amount of glucose produced by the liver.
5. Oral treatment option: Provides an oral combination option for eligible patients when both ingredients are appropriate.
6. Support for comprehensive diabetes care: Can be used alongside prescribed dietary measures, physical activity and regular blood glucose monitoring.
The clinical response varies between individuals. Potential adverse effects, kidney function and the suitability of the fixed-dose combination must be reviewed by a healthcare professional.
Pharmaceutical buyers searching for a Sitagliptin 50 mg + Metformin 1000 mg supplier India should verify product authenticity, current availability, approved specifications and relevant documentation.
A Sitagliptin 50 mg + Metformin 1000 mg Tablet wholesaler and distributor India enquiry should cover seller authorization, product sourcing, stock status, storage practices, batch traceability and applicable commercial terms.
Businesses seeking a Sitagliptin 50 mg + Metformin 1000 mg bulk supplier India should confirm pack sizes, minimum order quantities, available stock, delivery arrangements and remaining shelf life before placing an order.
A Sitagliptin 50 mg + Metformin 1000 mg pharmaceutical distributor India enquiry should esTabletlish which entity is authorized to supply the formulation and whether the proposed transaction complies with applicable pharmaceutical distribution requirements.
4. How Does It Work?
Sitagliptin inhibits the DPP-4 enzyme, slowing the breakdown of incretin hormones such as GLP-1 and GIP. These hormones help increase insulin secretion in a glucose-dependent manner and reduce glucagon secretion when blood glucose is elevated.
Metformin primarily decreases glucose production by the liver and improves insulin sensitivity in the body. These actions help regulate blood glucose levels.
Together, the ingredients provide complementary approaches to managing type 2 diabetes. The medicine does not cure diabetes, and its effectiveness depends on the patient’s clinical condition, treatment adherence and ongoing medical care.
5. Directions for Use
– Dosage: Take only as prescribed by a doctor. The appropriate regimen depends on the patient’s current treatment, blood glucose control, kidney function and approved product information.
– Administration: Follow the approved product label and pharmacist’s instructions. Metformin-containing medicines are commonly taken with meals to reduce gastrointestinal discomfort; confirm the directions for this specific formulation.
– Regular timing: Take the medicine consistently according to the prescribed schedule.
– Tablet handling: Follow the product label. Do not crush or split the Tablet unless the approved instructions or healthcare professional confirm that this is appropriate.
– Kidney function: Kidney function should be assessed before and during treatment as clinically indicated. This combination may not be suitable if either ingredient requires a different dose.
– Missed dose: Follow the doctor’s or pharmacist’s advice. Do not take a double dose to compensate.
– Lifestyle measures: Continue the recommended diet, physical activity and blood glucose monitoring plan.
The 1000 mg metformin strength may not be suitable for every patient. Do not start, stop or change the dose without medical advice.
6. Possible Side Effects
Possible adverse effects include:
– Nausea or vomiting
– Diarrhoea
– Abdominal discomfort
– Reduced appetite
– Headache
– Nasopharyngitis or upper respiratory tract symptoms
Important safety concerns include:
– Lactic acidosis: A rare but potentially life-threatening complication associated with metformin. Unusual weakness, muscle pain, breathing difficulty, unusual sleepiness or severe abdominal symptoms require urgent medical assessment.
– Pancreatitis: Persistent, severe abdominal pain, particularly if it radiates to the back, requires urgent medical evaluation.
– Hypoglycaemia: The risk may increase when the combination is used with insulin or sulfonylureas.
– Allergic reactions: Severe rash, swelling or breathing difficulty requires immediate medical attention.
– Vitamin B12 deficiency: Long-term metformin treatment may lower vitamin B12 levels in some patients.
– Severe joint pain or blistering skin reactions: These have been reported with sitagliptin and should be discussed promptly with a healthcare professional.
This list is not exhaustive. Refer to approved prescribing information and seek medical advice about persistent or concerning symptoms.
7. Safety Information
– Medical supervision: Use only under the guidance of a qualified healthcare professional.
– Kidney function: Assess renal function before treatment and periodically thereafter. Metformin is contraindicated in severe renal impairment; the fixed-dose combination may be unsuitable when renal function requires a different dose.
– Liver conditions: Inform the doctor about liver disease or other conditions that may increase the risk of lactic acidosis.
– Dehydration and acute illness: Severe vomiting, diarrhoea, dehydration, serious infection or other acute conditions can affect treatment safety. Contact the treating clinician for advice.
– Surgery and contrast imaging: Inform healthcare professionals about metformin use before surgery or investigations involving iodinated contrast. Temporary interruption may be necessary in certain circumstances.
– Pregnancy and breastfeeding: Consult a doctor before use during pregnancy, when planning pregnancy or while breastfeeding.
– Alcohol: Avoid excessive alcohol intake and discuss alcohol use with the prescribing clinician because it can increase the risk of metformin-associated lactic acidosis.
– Drug interactions: Inform the doctor about prescription medicines, over-the-counter products and supplements, especially other diabetes medicines.
– Contraindications: Do not use in patients with known serious hypersensitivity to either active ingredient or any component of the formulation. Follow the complete approved product information for other contraindications.
– Storage: Store in the original packaging according to the approved label, protected from excessive heat and moisture and out of reach of children.
This information is educational and does not replace approved prescribing information or individualized medical advice.
8. B2B Pharmaceutical Business Enquiries
CardianCare is associated with cardiac and diabetic healthcare products. Pharmaceutical procurement teams and eligible trade partners should contact the company directly to confirm its role in the product, current availability, approved product information and any applicable commercial arrangements.
Businesses searching for a Sitagliptin 50 mg + Metformin 1000 mg PCD pharma franchise India opportunity should first confirm whether CardianCare currently offers this programme and whether the product is included. Territory availability, eligibility and commercial terms must be verified directly.
For a Sitagliptin 50 mg + Metformin 1000 mg Tablets PCD pharma franchise enquiry, prospective partners should request written confirmation of the programme, product availability, licensing requirements and any promotional or commercial support.
Companies exploring a Sitagliptin 50 mg + Metformin 1000 mg Tablet PCD franchise should not assume the product is included in a franchise portfolio until CardianCare confirms it.
Businesses investigating Sitagliptin 50 mg + Metformin 1000 mg third party manufacturing India services must verify whether CardianCare actually provides such services. If another manufacturer is involved, confirm the facility’s authorization, applicable quality standards, product approvals and responsibilities.
A Sitagliptin 50 mg + Metformin 1000 mg Tablet third party manufacturer India enquiry should esTabletlish the proposed manufacturer’s identity, manufacturing-site authorization, approved specifications, quality systems and batch-release arrangements.
Companies researching Sitagliptin 50 mg + Metformin 1000 mg contract manufacturing India should request direct confirmation of service availability and clarify manufacturing permissions, regulatory responsibilities, technical documentation, quality agreements, batch quantities and commercial terms.
Contact CardianCare through its official company channels to enquire about product information and confirm any available business arrangements. Manufacturing, supply, wholesale, distribution, franchise and contract-manufacturing services must not be advertised as available without explicit company confirmation.
For more information about SITADOL-M 50/1000 Tablet (Sitagliptin 50 mg + Metformin 1000 mg), click here












Reviews
There are no reviews yet.